BIOLIGHT(SZ:300246)2026-02-11 07:56Financial Performance - Guangdong Baolite Medical Technology Co., Ltd. (宝莱特) expects a net loss of 60 million to 80 million yuan for 2025, compared to a loss of 71.44 million yuan in the previous year[2]. - The net profit after deducting non-recurring gains and losses is projected to be a loss of 68 million to 95 million yuan, down from a loss of 96.54 million yuan last year[2]. Reasons for Losses - The primary reasons for the expected losses include a decline in gross margin due to competitive pricing pressures, inventory and equipment impairments, and foreign exchange losses[3]. - The company is facing significant risks from ongoing medical procurement policies and price reductions in its product categories[3]. Cash Flow and Financial Health - The company reported a net cash inflow from operating activities of 38 million yuan for the first nine months of 2025, with cash reserves of 648 million yuan as of September 2025, effectively covering short-term debts[4]. - The company's financial condition is assessed as weak, with a leverage score of 6/9 and liquidity score of 6/7[6]. Business Operations - The new production line of the subsidiary Suzhou Junkang Medical Technology Co., Ltd. has commenced operations, but there are uncertainties regarding order volume and capacity absorption[4]. Credit Rating and Outlook - The company's credit rating remains at AA- with a negative outlook, reflecting ongoing challenges in the blood purification market and competitive pressures[4]. - The rating agency will continue to monitor the competitive landscape and its impact on the company's credit rating and outlook[4]. Overall Business Situation - The overall business situation is rated at 5/7, indicating moderate performance in the current market environment[6].